DNMT3A and cyclic hematopoiesis: Findings that support this observation include recent reports of DNMT3A CH in hematopoietic stem cell (HSC) grafts, which were shown to produce better outcomes in HSC transplant patients who did not receive post-transplant graft vs. host disease prevention with cyclophosphamide (PTCy) [15].